- Open Access
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors
© Woodrum et al; licensee BioMed Central Ltd. 2010
- Received: 30 September 2009
- Accepted: 10 February 2010
- Published: 10 February 2010
Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor disorder characterized by the growth of hamartomas in various organs including the kidney, brain, skin, lungs, and heart. Rapamycin has been shown to reduce the size of kidney angiomyolipomas associated with TSC; however, tumor regression is incomplete and kidney angiomyolipomas regrow after cessation of treatment. Mouse models of TSC2 related tumors are useful for evaluating new approaches to drug therapy for TSC.
In cohorts of Tsc2+/- mice, we compared kidney cystadenoma severity in A/J and C57BL/6 mouse strains at both 9 and 12 months of age. We also investigated age related kidney tumor progression and compared three different rapamycin treatment schedules in cohorts of A/J Tsc2+/- mice. In addition, we used nude mice bearing Tsc2-/- subcutaneous tumors to evaluate the therapeutic utility of sunitinib, bevacizumab, vincristine, and asparaginase.
TSC related kidney disease severity is 5-10 fold higher in A/J Tsc2+/- mice compared with C57BL/6 Tsc2+/- mice. Similar to kidney angiomyolipomas associated with TSC, the severity of kidney cystadenomas increases with age in A/J Tsc2+/- mice. When rapamycin dosing schedules were compared in A/J Tsc2+/- cohorts, we observed a 66% reduction in kidney tumor burden in mice treated daily for 4 weeks, an 82% reduction in mice treated daily for 4 weeks followed by weekly for 8 weeks, and an 81% reduction in mice treated weekly for 12 weeks. In the Tsc2-/- subcutaneous tumor mouse model, vincristine is not effective, but angiogenesis inhibitors (sunitinib and bevacizumab) and asparaginase are effective as single agents. However, these drugs are not as effective as rapamycin in that they increased median survival only by 24-27%, while rapamycin increased median survival by 173%.
Our results indicate that the A/J Tsc2+/- mouse model is an improved, higher through-put mouse model for future TSC preclinical studies. The rapamycin dosing comparison study indicates that the duration of rapamycin treatment is more important than dose intensity. We also found that angiogenesis inhibitors and asparaginase reduce tumor growth in a TSC2 tumor mouse model and although these drugs are not as effective as rapamycin, these drug classes may have some therapeutic potential in the treatment of TSC related tumors.
- mTOR Inhibitor
- Tuberous Sclerosis Complex
Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor disorder characterized by the manifestation of hamartomas in various organs including the kidney, brain, skin, lungs, and heart [1–3]. This multi-system disorder is fairly common, occurring at a frequency of 1:6000. The morbidity associated with TSC includes cognitive impairment, seizures, epilepsy, cortical tubers, cardiac rhabdomyomas, facial angiofibromas, and pulmonary lymphangioleiomyomatosis (LAM). Additionally, a majority of TSC patients experience renal manifestations such as kidney angiomyolipomas and/or kidney cysts. Kidney angiomyolipomas are age related tumors that occur in 60-80% of older children and adults with TSC [4, 5] and approximately 50% of women with sporadic LAM . Sporadic LAM is a progressive pulmonary disorder that is genetically related to TSC in that somatic mutations in the TSC1 or TSC2 genes have been identified in abnormal lung tissues from LAM patients .
TSC results from the loss of function of one of two genes, TSC1 or TSC2, whose gene products are hamartin and tuberin, respectively [8, 9]. These two gene products form a tumor suppressor complex that functions to inhibit mTOR activity in a conserved cellular signaling pathway which is responsible for cell proliferation, protein synthesis, and nutrient uptake [10, 11]. The key proteins in this pathway include PI3K, Akt, TSC1/TSC2, Rheb, and mTOR. The multiple roles of this important regulatory pathway have been described in recent reviews [12–16]. The inhibitory function of the tuberin-hamartin complex results from tuberin's GTP-ase activity on Rheb, which directly regulates mTOR kinase activity . When conditions are unfavorable for cell growth and the TSC1/TSC2 complex is functioning properly, Rheb-GTP is converted to the GDP form and mTOR kinase activity is decreased. When mutations occur in TSC1 or TSC2, the hamartin-tuberin complex is nonfunctional, Rheb-GTP is favored, and mTOR kinase is constitutively activated causing hyperphosphorylation of the downstream effectors (p70 S6 kinase and 4E-binding protein1) resulting in increased protein translation, cell growth, proliferation, and survival.
Several TSC genotype-phenotype studies show that TSC2 disease is both more common and more severe than TSC1 disease [3, 17–19]. The Tsc2+/- mouse is a good model for TSC related kidney disease because it is genetically similar to the majority of those with TSC, it develops age related kidney tumors (cystadenomas), and the mTOR pathway defect that occurs in the kidney tumors of Tsc2+/- mice is similar to that observed in human TSC related tumors [20–23]. Nude mice bearing subcutaneous Tsc2-/- tumors derived from mouse embryo fibroblasts are another useful animal model for TSC related tumors. The Tsc2-/- subcutaneous tumor model is a good generic model for TSC-related tumors because loss of heterozygosity (LOH) has been found in many TSC-related kidney and brain tumors [21, 24, 25].
Rapamycin (Rapamune™ or sirolimus, Wyeth, Madison, NJ) is a macrolide antibiotic that acts to inhibit the mTOR pathway and is FDA approved for use as an immunosuppressant following organ transplantation . More recently, two rapamycin analogs (temsirolimus and everolimus) have been approved for the treatment of renal cell carcinoma [27, 28]. Rapamycin (and analogs) have been shown to restore disregulated mTOR signaling in cells with abnormal TSC1 and/or TSC2 and to successfully treat kidney lesions in the Tsc2+/- mouse model along with other rodent models [20, 21, 29–31]. Furthermore, in early clinical trials evaluating the utility of rapamycin for the treatment of kidney angiomyolipomas associated with TSC and/or LAM, partial tumor regression has been observed in the majority of cases. Because responses are incomplete, not all tumors respond to drug therapy, and patients experience kidney angiomyolipoma regrowth after cessation of treatment [32–34], further studies are needed to evaluate longer duration mTOR inhibitor treatment and also to identify other active drugs.
There is evidence that other drug classes, such as those that alter amino acid metabolism, inhibitors of VEGF signaling, and microtubule inhibitors may be useful in treating TSC. The presence or absence of amino acids is an important regulator of mTOR signaling . L-Asparaginase is an enzyme that catalyzes the hydrolysis of L-asparagine to L-aspartic acid and is used as part of the curative combination chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) . The anti-tumor effect of L-asparaginase is attributed to the depletion of the L-asparagine, but since some preparations have glutaminase activity, glutamine may also be depleted depending on the source of L-asparaginase. It has been shown that human leukemic cells treated with L-asparaginase have reduced levels of the mTOR pathway's targets p70 S6 kinase (p70s6k) and 4E-binding protein 1 (4E-BP1) . Furthermore, there are tissue specific changes in mTOR pathway inhibition and cellular stress response signals in mice treated with L-asparaginase . Due to its inhibitory effects on growth of malignant cells and mTOR pathway activity in some tissues, L-asparaginase may be useful in treating TSC related tumors.
Vascular endothelial growth factor (VEGF) signaling is thought to play an important role in the pathogenesis of TSC and LAM. Since the brain, skin, and kidney tumors associated with TSC are vascular  and TSC2 loss is associated with increased levels of HIF and VEGF in cultured cells , VEGF is a potential target for TSC treatment. Furthermore, recent studies have shown that serum VEGF-D levels are elevated in patients with sporadic or TSC-associated LAM compared with healthy controls and patients with other pulmonary ailments [41–43]. The importance of VEGF signaling in the pathogenesis of TSC suggests that VEGF inhibitors as single agents or in combination with mTOR inhibitors may provide a promising treatment. Sorafenib (also known as BAY 43-9006 and Nexavar) is an oral multi-targeted kinase inhibitor that blocks vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, the RAF/Mek/Erk pathway, PDGFR, FLT-3, and C-KIT [44, 45]. It is FDA approved for the treatment of advanced renal cell and hepatocellular carcinoma [46, 47]. We have previously shown that the combination of sorafenib plus rapamycin is more effective than single agents in TSC tumor preclinical studies (Lee et al., 2009), but have not tested other VEGF signaling pathway inhibitors. Sunitinib (also known as SU11248 and Sutent) is a receptor tyrosine kinase inhibitor that targets both VEGF-R and platelet derived growth factor receptor (PDGF-R). Sunitinib has been shown to increase response and survival in patients with metastatic renal cell carcinoma (RCC)  and is also approved for the treatment of gastrointestinal stromal tumors . Bevacizumab (also known as rhMAb-VEGF and Avastin) is a recombinant humanized monoclonal antibody that binds all human VEGF isoforms and is approved for the treatment of colon, breast, non-small cell lung cancer, and glioblastoma [50–54] and also prolongs the time to progression of disease in metastatic RCC [55, 56]. The inhibitory effects of sunitinib and bevacizumab on VEGF signaling suggest that they may be useful in the treatment of TSC-related tumors.
Recent studies have shown that the TSC1/TSC2 complex may be important for microtubule-dependent protein transport because microtubule distribution and protein transport are disrupted in cells lacking Tsc1 or Tsc2. . This raises the possibility that microtubule inhibitors may have useful anti-tumor activity for TSC related tumors. Vincristine is an anti-neoplastic microtubule inhibitor that binds tubulin dimers to arrest rapidly dividing cells in metaphase [58, 59]. It is used in combination with other drugs in the treatment of lymphoma and leukemia. The defects in microtubule organization and function observed in Tsc1 and Tsc2 null cells suggests they may be sensitive to vincristine or other microtubule inhibitors.
In order to identify novel approaches for the treatment of tumors associated with TSC, we used two models of TSC related tumors in a series of preclinical studies. Tsc2+/- mice were used to compare disease severity of kidney disease in two different mouse strains (C57BL/6 and A/J), evaluate the age related progression of kidney disease (in A/J mice), and compare three different dosing schedules of rapamycin (daily, daily plus weekly, and weekly). We used a subcutaneous Tsc2-/- tumor model to evaluate the efficacy of two VEGF inhibitors (sunitinib and bevacizumab), asparaginase, and a microtubule inhibitor (vincristine).
Baseline tumor burden for untreated A/J versus C57BL/6 Tsc2+/- mice and age related kidney disease in A/J Tsc2+/- mice
The Tsc2+/- mouse is heterozygous for a deletion of exons 1-2 as previously described . In order to determine the baseline tumor burden for untreated Tsc2+/- in the A/J and C57BL/6 backgrounds, strain specific colonies of each background were created. Strain specific colonies were created for both the A/J and C57BL/6 background by backcrossing female Tsc2 heterozygous offspring with their pure strain Tsc2 wildtype fathers until the N5 generation was reached. Mice from the N5 generations were assigned to cohorts based on age, gender, and genotype. The cohorts were: Tsc2+/- 9 months consisting of 8 males and 8 females, Tsc2+/+ 9 months consisting of 2 males and 2 females, Tsc2+/- 12 months consisting of 4 males and 4 females, and Tsc2+/+ 12 months consisting of 2 males and 2 females. To determine the age related kidney disease in the A/J background, A/J Tsc2+/- mice were assigned to three additional cohorts. The cohorts were: A/J Tsc2+/- 3 months, A/J Tsc2+/- 5 months, and A/J Tsc2+/- 7 months. Each cohort contained 4 mice.
Mice were sacrificed according to age and cohort assignment. Upon sacrifice, kidneys, livers, and lungs were examined. All animals in Tsc2+/- cohorts had gross kidney lesions. There were no obvious liver tumors. Three A/J Tsc2+/- animals had gross lung abnormalities (1 in the untreated 3 month cohort, and 2 in the cohort treated with weekly rapamycin × 12 weeks) and one mouse, from the cohort treated with weekly rapamycin × 12 weeks, had a superficial tail tumor. Since non-kidney tumors were rare events, these were not studied further. We also looked at Tsc2+/+ cohorts at nine and twelve months of age and observed no gross or microscopic kidney lesions.
Quantification of kidney cystadenomas in Tsc2+/- mice
For histological quantification of kidney cystadenomas, each kidney was prepared as previously described . All cystadenomas were counted, measured, and scored according to the scale shown in Additional File 1 by a blinded researcher (CW or AN). Since the kidney cystadenomas of these Tsc2+/- mice can be divided into the subgroups cystic, pre-papillary, papillary and solid lesions, we use "kidney cystadenomas" to refer to the entire spectrum of kidney lesions observed. In addition to analyzing data according to all cystadenomas, a subgroup analysis was also done by coding cystic, pre-papillary, papillary, and solid kidney lesions separately. The scale used to define cystadenoma subtypes is shown in Additional File 2.
Rapamycin dosing schedules in A/J Tsc2+/- mice
A/J Tsc2+/- mice were assigned to one of three different rapamycin treatment cohorts (Groups 1-3) or an untreated control group (Group 4). The rapamycin cohorts included the following schedules: daily × 4 weeks plus weekly × 8 weeks (Group 1), daily × 4 weeks (Group 2), weekly × 12 weeks (Group 3). All animals started treatment at nine months of age and were euthanized twelve weeks later. Mice in Group 1 were treated with 8 mg/kg rapamycin administered by intraperitoneal injection (IP) Monday through Friday for four weeks followed by weekly doses of 8 mg/kg rapamycin IP for eight weeks. Mice in Group 2 were treated with 8 mg/kg rapamycin IP Monday through Friday for four weeks and received no drug treatment for the next 8 weeks. Mice in Group 3 were treated with weekly 8 mg/kg rapamycin IP for twelve weeks. Rapamycin powder was obtained from LC Laboratories (Woburn, MA) and a 20 mg/ml stock of rapamycin was made in ethanol (stored at -20°C for up to one week). The stock solution was diluted to 1.2 mg/ml in vehicle (0.25% PEG, 0.25% Tween-80) for the 8 mg/kg dose. Rapamycin treatments were administered within two hours of their preparation. All animals were checked daily (5 days per week), and general health and behavior were noted. All rapamycin treated animals were weighed at 9 months (at the start of rapamycin treatment), and again at the time of euthanasia at ~12 months (see Additional File 3). All mice were euthanized at approximately twelve months of age according to institutional animal care guidelines. The severity of kidney disease was calculated using quantitative histopathology as described previously. Untreated A/J Tsc2+/- mice from the 9 month and 12 month cohorts were weighed at the time of necropsy for comparison. All experiments were done according to animal protocols approved by our institutional animal protocol review committee (Children's Hospital Boston, Boston, MA) and were compliant with federal, local, and institutional guidelines on the care of experimental animals.
Treatment of subcutaneous tumors with asparaginase, vincristine, sunitinib, bevacizumab, and rapamycin
Nude mice (strain CD-1nuBR, up to 6-8 weeks old) were obtained from Charles River Laboratories, Inc. (Wilmington, Massachusetts) and injected subcutaneously on the dorsal flank with 2.5 million NTC/T2null (Tsc2-/-, Trp53-/-) cells. NTC/T2null cells are mouse embryonic fibroblasts that have been described previously . A total of 80 CD-1 nude mice were divided into 10 randomly assigned groups: untreated control group, single agent rapamycin, single agent asparaginase, combination asparaginase plus rapamycin, single agent vincristine, combination vincristine plus rapamycin, single agent sunitinib, combination sunitinib plus rapamycin, single agent bevacizumab, and combination bevacizumab plus rapamycin. As soon as tumors became visible, they were measured Monday through Friday using calipers. Tumor volumes were calculated using the formula: length × width × width × 0.5. All mice began treatment when tumors reached a volume of ~100 mm3. All mice were euthanized once tumors reached ~3000 mm3 in accordance with institutional animal care guidelines.
Untreated mice did not receive any treatment even after tumors reached a volume ≥ 100 mm3. Rapamycin treated groups received 200 μl of a 1.2 mg/ml solution of rapamycin (8 mg/kg) three times per week (on Mondays, Wednesdays, and Fridays) by IP injection. Doses of asparaginase, vincristine, sunitinib, and bevacizumab were selected based on anti-tumor activity in published preclinical studies [38, 62–64]. Asparaginase treated groups received 200 μl of a 300 IU/mL solution of asparaginase on Mondays and Thursdays for 4 weeks by IP injection. Vincristine treated groups received 200 μl of a 0.075 mg/mL solution of vincristine once per week for four weeks by IP injection. Sunitinib treated groups received 200 μl of a 12 mg/mL solution of sunitinib daily (Monday-Friday) by gavage. Bevacizumab treated groups received 200 μl of 0.75 mg/mL solution of bevacizumab once every two weeks by IP injection. All drug doses were calculated assuming a weight of 30 g per mouse. Asparaginase powder was obtained from the Brigham and Women's Hospital Research Pharmacy (Boston, MA) and diluted in sterile PBS. Vincristine was obtained in a 1 mg/mL solution from the Brigham and Women's Hospital Research Pharmacy (Boston, MA) and diluted in sterile PBS. Bevacizumab was obtained in a 25 mg/mL solution from the Brigham and Women's Hospital Research Pharmacy (Boston, MA) and diluted in sterile phosphate buffered saline (PBS). Sunitinib powder was obtained from LC Laboratories (Woburn, MA) and diluted in a sterile 5% glucose solution. Rapamycin powder was obtained from LC Laboratories (Woburn, MA) and a 20 mg/mL stock of rapamycin was made in ethanol (stored at -20°C for up to one week). The stock solution was diluted to 1.2 mg/mL in vehicle (0.25% PEG-400, 0.25% Tween-80).
Animal behavior and health were monitored daily, and animals were weighed at the start of the study and at the time of necropsy. Six animals had to be euthanized early due to dehydration and weight loss (Additional File 4). The survival and tumor growth data for these animals were included in all analyses. All mice from rapamycin treated cohorts were euthanized 24 hours after the last rapamycin treatment upon reaching the endpoint tumor volume. Upon sacrifice, whole blood was obtained for drug level testing.
Whole blood rapamycin levels
Whole blood rapamycin levels were measured from a subset of animals treated with rapamycin in the nude mouse treatment studies described above. Blood was removed at necropsy 24 hours after the final treatment of rapamycin. Whole blood was obtained through cardiac puncture, dispensed into an EDTA-containing blood collection tube, and diluted with an equal volume of sterile PBS to ensure sufficient volume for rapamycin level analysis. All measured rapamycin levels were corrected according to sample dilution at time of analysis. Only bevacizumab plus rapamycin, sunitinib plus rapamycin and single agent rapamycin cohorts could be analyzed for rapamycin levels due to treatment schedules. Whole blood samples were tested for rapamycin levels at the Clinical Laboratory at Children's Hospital Boston (Boston, Massachusetts). The range of detection is 0.5 to 100 ng/ml of rapamycin.
GraphPad Prism software (version 4.01) was used for all data analysis, with a p-value ≤ 0.05 indicating statistical significance. All calculations were completed from raw data by two researchers (AN and CW). A standard unpaired t test was used to test all quantitative data, and the Mantel-Cox logrank analysis was used for survival data.
Kidney tumor severity is age related and increased in A/J Tsc2+/- mice compared with C57BL/6 Tsc2+/- mice
Average Score and Number of Cystadenomas per Kidney for A/J and C57BL/6 Tsc2+/- Cohorts
Tsc2 +/- Cohort
(strain, treatment, age)
Score per Kidney
(ave ± std dev)
Number per Kidney
(ave ± std dev)
% Reduction in Score per Kidney vs. Group 4
Number of Rapa Doses
Duration of Treatment
Total Dose per Mouse
C57BL/6, untreated, 12 months
15.19 ± 9.39
5.94 ± 2.79
A/J, untreated, 3 months
6.50 ± 4.60
4.00 ± 1.69
A/J, untreated, 5 months
33.00 ± 13.53
13.00 ± 4.28
A/J, untreated, 7 months
57.75 ± 18.24
22.50 ± 5.88
A/J, untreated, 9 months
74.47 ± 23.07
22.63 ± 6.66
**A/J, untreated, 12 months
120.20 ± 52.53
35.25 ± 14.22
*A/J rapa daily × 4 weeks then weekly × 8 weeks
21.50 ± 8.38
7.38 ± 2.83
*A/J rapa daily × 4 weeks
41.13 ± 25.33
13.25 ± 6.32
*A/J rapa weekly × 12 weeks
22.61 ± 9.89
8.17 ± 3.07
From previous studies, we have shown that the severity of kidney disease increases with age in C57BL/6 Tsc2+/- mice . In order to understand the progression of kidney tumor growth in A/J Tsc2+/- mice, data was collected at different time points. The average score per kidney for the A/J Tsc2+/- mice at 3 months, 5 months, and 7 months of age was 6.5, 33.0, and 57.7, respectively. It is important to note that the score per kidney for the A/J Tsc2+/- untreated 5 m cohort (33.00 ± 13.53) is significantly greater (p = 0.0010) than that of the C57BL/6 Tsc2+/- untreated 12 m cohort (15.19 ± 9.39). These data further confirm that the A/J Tsc2+/- strain develops more severe kidney disease than the C57BL/6 Tsc2+/- strain and will allow for higher through-put Tsc2+/- preclinical studies.
Comparison of three rapamycin dosing schedules in Tsc2+/- mice
In a prior preclinical study, we determined that daily rapamycin treatment for two months combined with a rapamycin maintenance dose once a week for five months dramatically reduced tumor burden by 94.5% as compared to the untreated control . However, because that study included only one single agent rapamycin treatment group in which animals were treated daily × 1 month, then weekly × 4 months, then daily × 1 month, we do not clearly understand the impact of weekly rapamycin treatment. In order to further evaluate the efficacy of rapamycin weekly maintenance dosing, here we compared three rapamycin dosing schedules in A/J Tsc2+/- mice (weekly, daily, daily plus weekly). All animals started treatment at 9 months of age and were euthanized 12 weeks after treatment started. As shown in Table 1 and Figure 1, all three treatment cohorts showed a significant decrease in the average cystadenoma score per kidney as compared to both the 9 month and 12 month A/J Tsc2+/- untreated control groups (number of cystadenomas gave similar trends). Additionally, rapamycin dosed daily × 4 weeks followed by weekly × 8 weeks (Group 1, score per kidney 21.5) was more effective than rapamycin dosed daily × 4 weeks with no weekly maintenance dosing (Group 2, score per kidney 41.1, p = 0.007).
This data indicates that there was some tumor regrowth during the 8 weeks off of treatment in Group 2. Interestingly, dosing rapamycin weekly × 12 weeks (Group 3, score per kidney 22.6) was equally effective compared with dosing rapamycin daily × 4 weeks plus weekly × 8 weeks (Group 1). This suggests that the duration of rapamycin exposure is the critical factor and dose intensity is less important as there was no benefit to giving the higher doses for the first 4 weeks in Group 1. According to drug level testing in whole blood for this and prior preclinical studies [20, 65], average rapamycin levels in whole blood are ~12-40 ng/ml from 24 hours to 6 days, and ~6 ng/ml on days 7-8 after a single 8 mg/kg dose. This indicates that weekly rapamycin dosing in mice correlates well with clinical dosing in humans for which the typical range for target trough (24 hour) levels is 3-20 ng/ml.
Kidney cystadenoma subtypes are similar in A/J and C57BL/6 cohorts and shift to more pre-papillary and cystic lesions with rapamycin treatment
Distribution of Kidney Lesion Subtype for A/J and C57BL/6 Tsc2+/- Cohorts
% of Total Score per Kidney
Tsc2+/-Cohort (strain, treatment, age)
C57BL/6, untreated, 9 months
C57BL/6, untreated, 12 months
A/J, untreated, 3 months
A/J, untreated, 5 months
A/J, untreated, 7 months
A/J, untreated, 9 months
A/J, untreated, 12 months
A/J rapa daily × 4 weeks then weekly × 8 weeks
A/J rapa daily × 4 weeks
A/J rapa weekly × 12 weeks
Treatment of Tsc2-/- subcutaneous tumors with angiogenesis inhibitors, asparaginase, and vincristine
Summary of Tsc2-/- Subcutaneous Tumor Data (Vincristine, Asparaginase, Sunitinib, and Bevacizumab)
Combination Vincristine plus Rapamycin
Combination Asparaginase plus Rapamycin
Combination Sunitinib plus Rapamycin
Combination Bevacizumab plus Rapamycin
Number of mice (n)
Median Survival (days)
P value (survival)
Day 23, average tumor volume ± SEM (mm3)
1557 ± 260
352 ± 149
2289 ± 242
P Value (Day 23)
Day 30, average tumor volume ± SEM (mm3)
2618 ± 187
545 ± 212
330 ± 101
1978 ± 167
441 ± 97
1886 ± 287
545 ± 114
1233 ± 366
813 ± 449
P Value (Day 30)
Day 65, average tumor volume ± SEM (mm3)
1349 ± 302
2050 ± 384
1570 ± 378
1643 ± 246
1652 ± 557
P Value (Day 65)
Rapamycin (IP, 3 days per week)
8 mg/kg, 3 days per week
8 mg/kg, 3 days per week
8 mg/kg, 3 days per week
8 mg/kg, 3 days per week
8 mg/kg, 3 days per week
Vincristine (IP, weekly × 4 weeks)
0.5 mg/kg, weekly × 4 weeks
0.5 mg/kg, weekly × 4 weeks
Asparaginase (IP, Mon, Thurs × 4 weeks)
2 IU/g, Mon, Thurs × 4 weeks
2 IU/g, Mon, Thurs × 4 weeks
Sunitinib (Gavage, Mon-Fri)
80 mg/kg, Mon- Fri
80 mg/kg, Mon- Fri
Bevacizumab (IP, once/2 weeks)
5 mg/kg, once/2 weeks
5 mg/kg, once/2 weeks
Single agent asparaginase improves survival and reduces Tsc2-/- tumor growth. The day 30 average tumor volume for the asparaginase cohort (1978 ± 167 mm3) and the untreated cohort (2618 ± 187 mm3) are significantly different (p = 0.0405). The average tumor volumes at day 65 for the asparaginase plus rapamycin cohort (1570 ± 378 mm3) and the rapamycin cohort (1349 ± 302 mm3) are similar (Figure 3a, Table 3). The median survival of the single agent asparaginase cohort (39.5 days) and the median survival of the untreated cohort (31 days) are significantly different (p = 0.0101). However, the median survival of the asparaginase plus rapamycin treated cohort (71 days) is not significantly different than the median survival of the single agent rapamycin treated cohort (84.5 days, Figure 3b, Table 3). The slightly lower median survival in the asparaginase plus rapamycin combination group suggests that adding asparaginase to rapamycin may enhance tumor growth in some cases, although the mechanism is not known. In summary, asparaginase as a single agent is effective at reducing tumor growth and increasing survival when compared to the untreated cohort. Single agent asparaginase is not as effective as rapamycin at decreasing tumor volume or increasing survival. Furthermore, adding asparaginase to rapamycin did not reduce disease severity when compared to single agent rapamycin.
Single agent sunitinib improves survival in mice bearing Tsc2-/- tumors. The day 30 average tumor volume for the sunitinib cohort (1886 ± 287 mm3) was smaller than that of the untreated cohort (2618 ± 187 mm3), but this difference was not statistically significant. The average tumor volumes at day 65 for the sunitinib plus rapamycin cohort (1643 ± 246 mm3) and the rapamycin cohort (1349 ± 302 mm3) are similar (Figure 4a, Table 3). The median survival of the single agent sunitinib cohort (39 days) and the median survival of the untreated cohort (31 days) are significantly different (0.0193). However, the median survival of the sunitinib plus rapamycin treated cohort (80 days) is not significantly different than the median survival of the single agent rapamycin treated cohort (84.5 days, Figure 4b, Table 3). In summary, sunitinib as a single agent is effective at increasing survival, but not at reducing tumor growth, when compared to the untreated cohort. Single agent sunitinib is not as effective as rapamycin at decreasing tumor volume or increasing survival. Furthermore, adding sunitinib to rapamycin did not reduce disease severity when compared to single agent rapamycin.
Single agent bevacizumab improves survival and reduces Tsc2-/- tumor growth. The day 30 average tumor volume for the bevacizumab cohort (1233 ± 366 mm3) and the untreated cohort (2618 ± 187 mm3) are significantly different (p = 0.0172). The average tumor volumes at day 65 for the bevacizumab plus rapamycin cohort (1652 ± 557 mm3) and the rapamycin cohort (1349 ± 302 mm3) are similar (Figure 5a, Table 3). The median survival of the single agent bevacizumab cohort (38.5 days) and the median survival of the untreated cohort (31 days) are significantly different (p value = 0.0131). However, the median survival of the bevacizumab plus rapamycin treated cohort (60 days) is not significantly different than the median survival of the single agent rapamycin treated cohort (84.5 days, Figure 5b, Table 3). The slightly lower median survival in the bevacizumab plus rapamycin combination group suggests that adding bevacizumab to rapamycin may enhance tumor growth in some cases, although the mechanism is not known. In summary, bevacizumab as a single agent is effective at reducing tumor growth and increasing survival when compared to the untreated cohort. Single agent bevacizumab is not as effective as rapamycin at decreasing tumor volume or increasing survival. Furthermore, adding bevacizumab to rapamycin did not reduce disease severity when compared to single agent rapamycin.
Vincristine was not effective for the treatment of Tsc2-/- tumors. The day 23 average tumor volume for the vincristine cohort (2289 ± 242 mm3) and the untreated cohort (1557 ± 260 mm3) are not significantly different. The average tumor volumes at day 65 for the vincristine plus rapamycin cohort (2050 ± 384 mm3 and the rapamycin cohort (1349 ± 302 mm3) are similar. (Figure 6a, Table 3). Survival data shows that the median survival of the single agent vincristine cohort (26 days) does not differ significantly from the median survival of the untreated cohort (31 days). The median survival of the vincristine plus rapamycin treated cohort (77 days) is also not significantly different than the median survival of the single agent rapamycin treated cohort (84.5 days, Figure 6b, Table 3). In summary, vincristine as a single agent is not effective at reducing tumor growth and increasing survival when compared to the untreated cohort or the single agent rapamycin cohort. Furthermore, adding vincristine to rapamycin did not reduce disease severity when compared to single agent rapamycin.
Rapamycin drug levels in combination treated animals
Rapamycin is metabolized by CYP3A4 therefore drug levels can vary when there is exposure to other drugs that either induce or inhibit CYP3A4. To be sure there were no significant drug interaction issues in our studies, rapamycin levels were measured in tumors or whole blood 24 hours after the last dose in a subset of animals from our studies (Additional File 6). Average blood rapamycin levels in the sunitinib plus rapamycin group (137.9 ± 29.23 ng/ml), bevacizumab plus rapamycin group (94 ± 34.4 ng/ml), and the single agent rapamycin group (86.4 ± 0.86 ng/ml) were not statistically different. Rapamycin levels for the asparaginase plus rapamycin and vincristine plus rapamycin cohorts are not reported due to the treatment schedules of asparaginase and vincristine. Asparaginase and vincristine treatments were given for only 4 weeks and so had not been administered to mice in these cohorts for several weeks prior to the last dose of rapamycin. Based on drug level testing, we conclude that sunitinib and bevacizumab did not significantly affect the metabolism of rapamycin in the preclinical studies reported here.
Rapamycin treatment associated with lack of weight gain in nude mice bearing Tsc2-/- tumors
Six rapamycin treated nude mice bearing Tsc2-/- subcutaneous tumors required early euthanasia. The six mice presented with hunched posture, dehydration, and weight loss, and were euthanized per protocol standards. Each of the six mice belonged to different treatment cohorts; however, all of the mice received rapamycin treatment (Additional File 4). Because nude mice are immunodeficient and rapamycin is an immunosuppressant drug, these animals may be at higher risk for rapamycin toxicity. These toxicities prompted further review, as they have not been observed in our prior studies. As shown in Additional File 7, we noted a lack of weight gain in nude mouse cohorts treated with rapamycin. These toxicities also prompted a comparison of weights before and after treatment in our A/J Tsc2+/- experiment; there was no significant difference in weights before and after treatment in the rapamycin treated cohorts and there was no difference in the average weights of the untreated 9 month and 12 month cohorts (see Additional File 3). Although the average weight of one of the rapamycin treated cohorts (Group 2, rapamycin treated daily × 4 weeks) was lower than the untreated group at 12 months (Group 4), the difference was small. We did not observe any increased mortality in the rapamycin treated Tsc2+/- cohorts.
The Tsc2+/- mouse is an excellent mouse model for the study of TSC related kidney disease. We have previously used Tsc2+/- mice in a C57BL/6 mixed strain to show that mTOR inhibitor treatment reduces kidney tumor severity, to investigate the timing of mTOR inhibitor treatment, and to show that addition of prolonged weekly maintenance rapamycin treatment was extremely effective [20, 21, 61]. However, a major disadvantage of the Tsc2+/- mouse model in a predominantly C57BL/6 background is that kidney disease develops gradually so preclinical studies can take 12-18 months to complete. In this study, we sought to improve the Tsc2+/- mouse as a preclinical model for TSC tumor studies. Based on observations regarding strain differences reported in Onda et al. 1999 , we backcrossed the Tsc2+/- genotype onto A/J and C57BL/6 backgrounds, compared kidney disease severity, and found that the A/J strain shows a much higher kidney tumor burden than mice in the C57BL/6 background at 9 and 12 months of age as shown by the average score per kidney and average number of cystadenomas per kidney. Similar to TSC related kidney disease in humans, the tumor burden increases with age in both mouse strains. Interestingly, the A/J Tsc2+/- strain shows a significantly higher tumor burden at 5 months of age than the C57BL/6 Tsc2+/- strain at 12 months of age. Based on the findings of this study, the A/J strain Tsc2+/- mice have a 5-10 fold higher disease burden than C57BL/6 strain Tsc2+/- mice and are a superior and higher through-put Tsc2+/- mouse model for preclinical studies relevant to TSC kidney disease and tumors. Furthermore, because there is a dramatic difference in the severity of the kidney tumor phenotype in these two mouse strains, they could be used to identify modifier genes that impact the severity of TSC renal manifestations .
The potential utility of rapamycin treatment for a prolonged duration was suggested by the results of a previous preclinical study using C57BL/6 Tsc2+/- mice in which we noted that a rapamycin dosing schedule that included daily treatment for 2 months and weekly treatment for 6 months, resulted in a dramatic 94.5% reduction in kidney tumor severity . In that study, rapamycin (IP) was given at a dose of 8 mg/kg Monday through Friday from 6 to 7 months of age, followed by a maintenance dose of 16 mg/kg once a week from 7 to 12 months of age, followed by daily rapamycin treatment (8 mg/kg Monday through Friday) from 12 to 13 months of age. We also note that in previous CCI-779 preclinical studies, giving a lower dose over 3 months seemed to be more effective than a higher dose for 2 months (84% reduction with a total dose of 4.32 mg per mouse  versus 64% reduction with a total dose of 9.6 mg per mouse . These studies suggest that dosing of mTOR inhibitors at a low dose for a prolonged period of time may be the optimal strategy to maximize benefit and limit drug toxicity. However, a major limitation in understanding the impact of dose intensity, duration of therapy, and weekly mTOR inhibitor dosing based on our prior preclinical studies is that we have previously compared treatment groups from different preclinical studies with important inter-study differences. Because the issue of optimizing rapamycin dosing to maximize efficacy while limiting toxicity has clinical implications, here we further investigated the issue of rapamycin dosing schedule and dose intensity by directly comparing three different rapamycin treatment groups (daily × 4 weeks, daily × 4 weeks then weekly × 8 weeks, and weekly × 12 weeks). We found that optimal treatment correlated with duration of treatment, not total dose given. There was a 66% reduction with a total dose of 4.8 mg per mouse in the group treated daily × 4 weeks, an 82% reduction with a total dose of 6.72 mg per mouse in the group treated daily × 4 weeks plus weekly × 8 weeks, and an 81% reduction with a total dose of 2.88 mg per mouse in the group treated weekly × 12 weeks (see Table 1). These findings demonstrate that low dose rapamycin treatment for a longer duration of time is most effective in the Tsc2+/- mouse, and it would be reasonable to evaluate this dosing strategy in future TSC clinical trials.
Our findings also clearly demonstrate that the response of kidney tumors to rapamycin in the Tsc2+/- mouse correlates well with observations in early TSC angiomyolipoma clinical trials. In A/J Tsc2+/- mice, cystadenoma score per kidney in untreated animals at 9 months of age is 74.4, and cystadenoma score per kidney is 41.13 in the groups treated daily × 4 weeks, but 21.50 in the group treated daily × 4 weeks then weekly × 8 weeks (Table 1). Furthermore, the higher kidney tumor score in the group treated daily × 4 weeks (compared with the group treated daily × 4 weeks then weekly × 8 weeks) is consistent with tumor regrowth during months ~10-12 when no drug treatment was given. This result is analogous to what is observed in patients with kidney angiomyolipomas associated with TSC and/or LAM treated with rapamycin. In a cohort of 20 TSC and/or LAM patients treated with rapamycin for 12 months and then followed off of treatment at 18 months and 24 months, the average kidney angiomyolipoma volume was 71.6 ml at baseline, 36.5 ml at 12 months (~50% size reduction), 64.8 ml at 18 months, and 74.9 ml at 24 months . In both mice and humans, TSC related kidney tumors regress during rapamycin treatment and regrow when rapamycin treatment is stopped. This striking similarity further illustrates the clinical relevance of preclinical studies using the Tsc2+/- mouse model. There is also some early evidence that TSC tumor preclinical models are relevant to TSC brain manifestations as several mouse models with TSC related brain abnormalities (seizures or cognitive deficits) also had a reduction of disease severity with rapamycin treatment [67–69].
There is excitement regarding the recent clinical studies showing that rapamycin treatment causes TSC-related tumor regression. However, since regression is incomplete, and tumors regrow with cessation of treatment [32–34] there is significant interest in identifying novel agents for TSC-related tumors to be used either as single agents or in combination with rapamycin. In this study, we evaluated three novel drug classes in our Tsc2-/- subcutaneous tumor model: an enzyme that interferes with amino acid metabolism (asparaginase), two VEGF inhibitors (sunitinib and bevacizumab), and a microtubule inhibitor (vincristine). These drugs were tested both as single agents and in combination with rapamycin. We found that asparaginase, sunitinib, and bevacizumab are effective as single agents, but not as effective as rapamycin. Vincristine was not effective as a single agent. None of these drugs combined with rapamycin was more effective than single agent rapamycin treatment. Based on 24 hour rapamycin level measurements, there was no evidence that drug interaction issues influenced the outcome of rapamycin combination treatment with sunitinib or bevacizumab. Rapamycin levels were not tested in the combination groups with asparaginase or vincristine because of the dosing schedule used.
Although asparaginase, sunitinib, and bevacizumab had only a modest improvement (24-27%) in median survival compared to untreated control groups (p values = 0.010-0.019), this difference was statistically significant. In contrast, the improvement in median survival of rapamycin treatment was dramatic (173% compared with untreated, p value = < 0.0001). The positive results with asparaginase treatment are consistent with the known influence of amino acid depletion on the TSC1/TSC2-mTOR signaling pathway . Similarly, the positive results with sunitinib and bevacizumab are consistent with the known relevance of the VEGF signaling pathway in TSC related lesions and in vitro studies of TSC deficient cells [39, 40].
Summary of Survival Data for Effective Agents in the Tsc2-/- Subcutaneous Tumor Model
Percent Difference From Untreated
Tumor Volume of 100 mm3
8 mg/kg 3 days/wk
2IU/g twice/wk × 4 wks
Asparaginase + Rapamycin
2IU/g twice/wk × 4 wks + 8 mg/kg 3 days/wk
80 mg/kg 5 days/wk
Sunitinib + Rapamycin
80 mg/kg 5 days/wk + 8 mg/kg 3 days/wk
5 mg/kg once/2 wks
Bevacizumab + Rapamycin
5 mg/kg once/2 wks + 8 mg/kg 3 days/wk
Lee et al, 2009
Tumor Volume of 150 mm3
8 mg/kg 5 days/wk
60 mg/kg 5 days/wk
Sorafenib + Rapamycin
60 mg/kg 5 days/wk + 8 mg/kg 5 days/wk
Messina et al, 2007
Tumor Volume of 50 mm3 for early treatments, 250 mm3 for late treatments
8 mg/kg 5 days/wk
8 mg/kg 5 days/wk
8 mg/kg 5 days/wk
Lee et al, 2006
Tumor Volume of 300 mm3
8 mg/kg 5 days/wk
20,000 units 3 days/wk
IFN-γ + CCI-779
20,000 units 3 days/wk + 8 mg/kg 5 days/wk
Lee et al, 2005
18 Days after injection with Tsc2-/- cells
4 mg/kg 3 days/wk
20,000 units 3 days/wk
The preclinical studies reported here show that the A/J Tsc2+/- mouse model has younger onset TSC related kidney disease and as a result, is an improved mouse model for use in future preclinical studies. Our rapamycin dosing comparison results in A/J Tsc2+/- mice indicate that a longer duration of rapamycin treatment is more important than dose intensity, therefore low doses for a prolonged duration seems to be the best strategy. Since the response to mTOR inhibitors in Tsc2+/- mice correlates well with observations in rapamycin kidney angiomyolipoma trials, it would be reasonable to test this dosing strategy in future TSC clinical trials. We also present data showing evidence for tumor response to some new single agents including sunitinib, bevacizumab, and asparaginase. We have previously shown that single agent IFN-γ, combination IFN-γ plus mTOR inhibitor, and combination sorafenib plus mTOR inhibitor are effective in the Tsc2-/- subcutaneous tumor model. Since tumor responses to mTOR inhibitor treatment are much more dramatic than responses to other agents (see Table 4) and combination treatments are only a slight improvement over single agent mTOR inhibitor treatment, single agent mTOR inhibitor treatment seems to be the best initial strategy for medical treatment of problematic TSC related tumors. We conclude that clinical investigation of non-mTOR inhibitors as single agents or in combination with an mTOR inhibitor should be investigated as second line therapy for problematic TSC related tumors that are not responding to mTOR inhibitors. This work illustrates the clinical relevance of preclinical studies in mouse models of TSC2 related tumors. Future preclinical studies using these and related mouse models are likely to guide a rational approach to improving medical therapy for TSC related tumors and other manifestations of TSC.
The authors would like to thank Nancy Lee, Aubrey Rauktys, and Michael Messina for technical assistance. This research was funded by NIH (NIDDK) Grant number R01 DK066366, the Tuberous Sclerosis Alliance, and the Brigham and Women's Hospital Biomedical Research Institute. We also thank Megha Basavappa, Meghan Grimes, Vidhya Kumar, and Laifong Lee for their careful review of this manuscript.
- Gomez M, Sampson J, Whittemore V, eds: The tuberous sclerosis complex. 1999, Oxford University Press: Oxford, England, ThirdGoogle Scholar
- Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med. 2006, 355 (13): 1345-56. 10.1056/NEJMra055323.PubMedView ArticleGoogle Scholar
- Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ: Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs. Am J Hum Genet. 2001, 68 (1): 64-80. 10.1086/316951.PubMedView ArticleGoogle Scholar
- Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, Kwiatkowski DJ: Association between a High-Expressing Interferon-gamma Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. Am J Hum Genet. 2002, 71 (4): 750-758. 10.1086/342718.PubMedView ArticleGoogle Scholar
- Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES: Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998, 160 (1): 141-5. 10.1016/S0022-5347(01)63072-6.PubMedView ArticleGoogle Scholar
- Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP: Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol. 2007, 36 (4): 398-408. 10.1165/rcmb.2006-0372TR.PubMedView ArticleGoogle Scholar
- Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000, 97 (11): 6085-90. 10.1073/pnas.97.11.6085.PubMedView ArticleGoogle Scholar
- Consortium ECTS: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993, 75 (7): 1305-15.View ArticleGoogle Scholar
- van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Ouweland van den A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997, 277 (5327): 805-8. 10.1126/science.277.5327.805.PubMedView ArticleGoogle Scholar
- Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001, 15 (11): 1383-92. 10.1101/gad.901101.PubMedView ArticleGoogle Scholar
- Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 2001, 105 (3): 357-68. 10.1016/S0092-8674(01)00333-6.PubMedView ArticleGoogle Scholar
- Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell. 2006, 124 (3): 471-84. 10.1016/j.cell.2006.01.016.PubMedView ArticleGoogle Scholar
- Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008, 27 (41): 5497-510. 10.1038/onc.2008.245.PubMedView ArticleGoogle Scholar
- Chiang GG, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007, 13 (10): 433-42. 10.1016/j.molmed.2007.08.001.PubMedView ArticleGoogle Scholar
- Findlay GM, Harrington LS, Lamb RF: TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?. Curr Opin Genet Dev. 2005, 15 (1): 69-76. 10.1016/j.gde.2004.11.002.PubMedView ArticleGoogle Scholar
- Huang J, Manning BD: The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008, 412 (2): 179-90. 10.1042/BJ20080281.PubMedView ArticleGoogle Scholar
- Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & Development. 2003, 17 (15): 1829-34.View ArticleGoogle Scholar
- Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H: Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007, 9 (2): 88-100. 10.1097/GIM.0b013e31803068c7.PubMedView ArticleGoogle Scholar
- Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, Ouweland van den A: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005, 13 (6): 731-41. 10.1038/sj.ejhg.5201402.PubMedView ArticleGoogle Scholar
- Messina MP, Rauktys A, Lee L, Dabora SL: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol. 2007, 7: 14-10.1186/1471-2210-7-14.PubMedView ArticleGoogle Scholar
- Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer. 2005, 42 (3): 213-27. 10.1002/gcc.20118.PubMedView ArticleGoogle Scholar
- El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ: Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 2003, 361 (9366): 1348-9. 10.1016/S0140-6736(03)13044-9.PubMedView ArticleGoogle Scholar
- Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 2004, 63 (12): 1236-42.PubMedView ArticleGoogle Scholar
- Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet. 1996, 59 (2): 400-6.PubMedGoogle Scholar
- Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, Klein-Szanto AJ, Kwiatkowski DJ, Yeung RS: Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol. 1997, 151 (6): 1639-47.PubMedGoogle Scholar
- Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000, 19 (56): 6680-6. 10.1038/sj.onc.1204091.PubMedView ArticleGoogle Scholar
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, T O'Toole, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007, 356 (22): 2271-81. 10.1056/NEJMoa066838.PubMedView ArticleGoogle Scholar
- Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372 (9637): 449-56. 10.1016/S0140-6736(08)61039-9.PubMedView ArticleGoogle Scholar
- Ikeda S, Mochizuki A, Sarker AH, Seki S: Identification of functional elements in the bidirectional promoter of the mouse Nthl1 and Tsc2 genes. Biochem Biophys Res Commun. 2000, 273 (3): 1063-8. 10.1006/bbrc.2000.3071.PubMedView ArticleGoogle Scholar
- Kenerson H, Dundon TA, Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005, 57 (1): 67-75. 10.1203/01.PDR.0000147727.78571.07.PubMedView ArticleGoogle Scholar
- Lee L, Sudentas P, Dabora SL: Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer. 2006, 45 (10): 933-44. 10.1002/gcc.20357.PubMedView ArticleGoogle Scholar
- Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006, 59 (3): 490-8. 10.1002/ana.20784.PubMedView ArticleGoogle Scholar
- Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 200-3. 10.1056/NEJMc072500.PubMedView ArticleGoogle Scholar
- Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 140-51. 10.1056/NEJMoa063564.PubMedView ArticleGoogle Scholar
- Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K: Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene. 2006, 25 (48): 6361-72. 10.1038/sj.onc.1209882.PubMedView ArticleGoogle Scholar
- Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE: Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001, 97 (5): 1211-8. 10.1182/blood.V97.5.1211.PubMedView ArticleGoogle Scholar
- Iiboshi Y, Papst PJ, Hunger SP, Terada N: L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun. 1999, 260 (2): 534-9. 10.1006/bbrc.1999.0920.PubMedView ArticleGoogle Scholar
- Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG: Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006, 281 (42): 31222-33. 10.1074/jbc.M604511200.PubMedView ArticleGoogle Scholar
- Arbiser JL, Brat D, Hunter S, J D'Armiento, Henske EP, Arbiser ZK, Bai X, Goldberg G, Cohen C, Weiss SW: Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol. 2002, 46 (3): 376-80. 10.1067/mjd.2002.120530.PubMedView ArticleGoogle Scholar
- Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003, 4 (2): 147-58. 10.1016/S1535-6108(03)00187-9.PubMedView ArticleGoogle Scholar
- Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y: Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006, 4 (3): 143-52. 10.1089/lrb.2006.4.143.PubMedView ArticleGoogle Scholar
- Young LR, Inoue Y, McCormack FX: Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 199-200. 10.1056/NEJMc0707517.PubMedView ArticleGoogle Scholar
- Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J: Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009, 135 (5): 1293-300. 10.1378/chest.08-1160.PubMedView ArticleGoogle Scholar
- Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407: 597-612. 10.1016/S0076-6879(05)07047-3.PubMedView ArticleGoogle Scholar
- Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64 (19): 7099-109. 10.1158/0008-5472.CAN-04-1443.PubMedView ArticleGoogle Scholar
- Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 125-34. 10.1056/NEJMoa060655.PubMedView ArticleGoogle Scholar
- Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006, 24 (26): 4293-300. 10.1200/JCO.2005.01.3441.PubMedView ArticleGoogle Scholar
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 115-24. 10.1056/NEJMoa065044.PubMedView ArticleGoogle Scholar
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368 (9544): 1329-38. 10.1016/S0140-6736(06)69446-4.PubMedView ArticleGoogle Scholar
- Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357 (26): 2666-76. 10.1056/NEJMoa072113.PubMedView ArticleGoogle Scholar
- Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-50. 10.1056/NEJMoa061884.PubMedView ArticleGoogle Scholar
- Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009, 72 (14): 1217-22. 10.1212/01.wnl.0000345668.03039.90.PubMedView ArticleGoogle Scholar
- Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25 (12): 1539-44. 10.1200/JCO.2006.09.6305.PubMedView ArticleGoogle Scholar
- Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004, 7 (4): 335-45. 10.1007/s10456-004-8272-2.PubMedView ArticleGoogle Scholar
- Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003, 349 (5): 427-34. 10.1056/NEJMoa021491.PubMedView ArticleGoogle Scholar
- Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007, 370 (9605): 2103-11. 10.1016/S0140-6736(07)61904-7.PubMedView ArticleGoogle Scholar
- Jiang X, Yeung RS: Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Cancer Res. 2006, 66 (10): 5258-69. 10.1158/0008-5472.CAN-05-4510.PubMedView ArticleGoogle Scholar
- Mujagic H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE: Effects of vincristine on cell survival, cell cycle progression, mitotic accumulation in asynchronously growing Sarcoma 180 cells. Cancer Res. 1983, 43 (8): 3591-7.PubMedGoogle Scholar
- Himes RH, Kersey RN, Heller-Bettinger I, Samson FE: Action of the vinca alkaloids vincristine, vinblastine, desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976, 36 (10): 3798-802.PubMedGoogle Scholar
- Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ: TSC2+/- mice develop tumors in multiple sites which express gelsolin and are influenced by genetic background. J Clin Invest. 1999, 104 (6): 687-95. 10.1172/JCI7319.PubMedView ArticleGoogle Scholar
- Lee N, Woodrum C, Nobil A, Rauktys A, Messina MP, Dabora SL: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 2009, 9: 8-10.1186/1471-2210-9-8.PubMedView ArticleGoogle Scholar
- de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol. 2007, 9 (4): 412-23. 10.1215/15228517-2007-024.PubMedView ArticleGoogle Scholar
- Huynh H, Teo CC, Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther. 2007, 6 (11): 2959-66. 10.1158/1535-7163.MCT-07-0237.PubMedView ArticleGoogle Scholar
- Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004, 103 (10): 3905-14. 10.1182/blood-2003-08-2911.PubMedView ArticleGoogle Scholar
- Rauktys A, Lee N, Lee L, Dabora SL: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol. 2008, 8 (1): 1-10.1186/1471-5945-8-1.PubMedView ArticleGoogle Scholar
- Doetschman T: Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol. 2009, 530: 423-33. full_text.PubMedView ArticleGoogle Scholar
- Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ: Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008, 28 (21): 5422-32. 10.1523/JNEUROSCI.0955-08.2008.PubMedView ArticleGoogle Scholar
- Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ: Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008, 14 (8): 843-8. 10.1038/nm1788.PubMedView ArticleGoogle Scholar
- Zeng LH, Xu L, Gutmann DH, Wong M: Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008, 63 (4): 444-53. 10.1002/ana.21331.PubMedView ArticleGoogle Scholar
- Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP: Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA. 2009, 106 (8): 2635-40. 10.1073/pnas.0810790106.PubMedView ArticleGoogle Scholar
- Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D: Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer. 2009, 8: 38-10.1186/1476-4598-8-38.PubMedView ArticleGoogle Scholar
- El-Hashemite N, Walker V, Kwiatkowski DJ: Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res. 2005, 65 (6): 2474-81. 10.1158/0008-5472.CAN-04-3840.PubMedView ArticleGoogle Scholar
- Lenci I, Angelico M, Tisone G, Orlacchio A, Palmieri G, Pinci M, Bombardieri R, Curatolo P: Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment. J Hepatol. 2008, 48 (6): 1026-9. 10.1016/j.jhep.2008.01.036.PubMedView ArticleGoogle Scholar
- Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ: Renal and liver tumors in Tsc2+/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther. 2009, 8 (7): 1799-807. 10.1158/1535-7163.MCT-09-0055.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.